• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Durable Clinical Response to Crizotinib in IRF2BP2-NTRK1 Non-small-cell Lung Cancer.

作者信息

Wang Buhai, Gao Ye, Huang Yuxiang, Ou Qiuxiang, Fang Tingting, Tang Chunhui, Wu Xue, Shao Yang W

机构信息

Northern Jiangsu People's Hospital, Affiliated Hospital to Yangzhou University, Yangzhou, Jiangsu, China.

Northern Jiangsu People's Hospital, Affiliated Hospital to Yangzhou University, Yangzhou, Jiangsu, China.

出版信息

Clin Lung Cancer. 2019 May;20(3):e233-e237. doi: 10.1016/j.cllc.2018.12.017. Epub 2018 Dec 31.

DOI:10.1016/j.cllc.2018.12.017
PMID:30691963
Abstract
摘要

相似文献

1
Durable Clinical Response to Crizotinib in IRF2BP2-NTRK1 Non-small-cell Lung Cancer.克唑替尼对IRF2BP2-NTRK1非小细胞肺癌的持久临床反应
Clin Lung Cancer. 2019 May;20(3):e233-e237. doi: 10.1016/j.cllc.2018.12.017. Epub 2018 Dec 31.
2
Brigatinib versus crizotinib for ALK-positive NSCLC.布加替尼与克唑替尼治疗ALK阳性非小细胞肺癌的对比
Lancet Oncol. 2018 Nov;19(11):e585. doi: 10.1016/S1470-2045(18)30741-1. Epub 2018 Oct 4.
3
Crizotinib in advanced non-small-cell lung cancer with concomitant ALK rearrangement and c-Met overexpression.克唑替尼治疗伴有 ALK 重排和 c-Met 过表达的晚期非小细胞肺癌。
BMC Cancer. 2018 Nov 26;18(1):1171. doi: 10.1186/s12885-018-5078-y.
4
Effects of Treatment with Crizotinib on Non-small Cell Lung Carcinoma with ALK Translocation in the Czech Republic.克唑替尼治疗对捷克共和国ALK易位非小细胞肺癌的影响。
Klin Onkol. 2018 Spring;31(3):207-212. doi: 10.14735/amko2018207.
5
CUX1-ALK, a Novel ALK Rearrangement That Responds to Crizotinib in Non-Small Cell Lung Cancer.CUX1-ALK，一种新的 ALK 重排，对非小细胞肺癌的克唑替尼有反应。
J Thorac Oncol. 2018 Nov;13(11):1792-1797. doi: 10.1016/j.jtho.2018.07.008. Epub 2018 Aug 7.
6
Exploration of germline variants responsible for adverse events of crizotinib in anaplastic lymphoma kinase-positive non-small cell lung cancer by target-gene panel sequencing.通过靶向基因 panel 测序探究间变性淋巴瘤激酶阳性非小细胞肺癌中导致克唑替尼不良反应的种系变异。
Lung Cancer. 2019 Feb;128:20-25. doi: 10.1016/j.lungcan.2018.12.002. Epub 2018 Dec 4.
7
Management of Central Nervous System Metastases in Patients With Advanced Anaplastic Lymphoma Kinase-Rearranged Non-Small-Cell Lung Cancer During Crizotinib Treatment.克唑替尼治疗期间晚期间变性淋巴瘤激酶重排非小细胞肺癌患者中枢神经系统转移的管理。
Clin Lung Cancer. 2019 Nov;20(6):e631-e637. doi: 10.1016/j.cllc.2019.06.013. Epub 2019 Jun 18.
8
Next generation sequencing reveals a novel ALK G1128A mutation resistant to crizotinib in an ALK-Rearranged NSCLC patient.下一代测序揭示了一种新型的 ALK G1128A 突变，该突变对 ALK 重排 NSCLC 患者的克唑替尼耐药。
Lung Cancer. 2018 Sep;123:83-86. doi: 10.1016/j.lungcan.2018.07.004. Epub 2018 Jul 6.
9
Clinical factors affecting progression-free survival with crizotinib in ALK-positive non-small cell lung cancer.ALK 阳性非小细胞肺癌中克唑替尼无进展生存期的临床影响因素。
Korean J Intern Med. 2019 Sep;34(5):1116-1124. doi: 10.3904/kjim.2018.011. Epub 2018 Jun 29.
10
ROS1-ADGRG6: a case report of a novel ROS1 oncogenic fusion variant in lung adenocarcinoma and the response to crizotinib.ROS1-ADGRG6：肺腺癌中一种新型 ROS1 致癌融合变异的病例报告及对克唑替尼的反应。
BMC Cancer. 2019 Aug 5;19(1):769. doi: 10.1186/s12885-019-5948-y.

引用本文的文献

1
Gene Fusions in Non-Small-Cell Lung Cancer: Real-World Screening Data of 1068 Unselected Patients.非小细胞肺癌中的基因融合：1068例未经筛选患者的真实世界筛查数据
Cancers (Basel). 2023 May 29;15(11):2966. doi: 10.3390/cancers15112966.
2
The nerve growth factor-delivered signals in prostate cancer and its associated microenvironment: when the dialogue replaces the monologue.神经生长因子在前列腺癌及其相关微环境中传递的信号：当对话取代独白时。
Cell Biosci. 2023 Mar 20;13(1):60. doi: 10.1186/s13578-023-01008-4.
3
Survival benefit of combinatorial osimertinib rechallenge and entrectinib in an EGFR-mutant NSCLC patient with acquired LMNA-NTRK1 fusion following osimertinib resistance.
奥希替尼耐药后，联合使用奥希替尼再挑战和恩曲替尼对一名获得性LMNA-NTRK1融合的EGFR突变非小细胞肺癌患者的生存获益。
Respirol Case Rep. 2022 Oct 17;10(11):e01054. doi: 10.1002/rcr2.1054. eCollection 2022 Nov.
4
NTRK Fusion in Non-Small Cell Lung Cancer: Diagnosis, Therapy, and TRK Inhibitor Resistance.非小细胞肺癌中的NTRK融合：诊断、治疗及TRK抑制剂耐药性
Front Oncol. 2022 Mar 17;12:864666. doi: 10.3389/fonc.2022.864666. eCollection 2022.
5
The Transcriptional Co-factor IRF2BP2: A New Player in Tumor Development and Microenvironment.转录辅因子IRF2BP2：肿瘤发生与微环境中的新角色
Front Cell Dev Biol. 2021 Apr 29;9:655307. doi: 10.3389/fcell.2021.655307. eCollection 2021.
6
Unclassified mesenchymal sarcoma with NTRK1-KHDRBS1 gene fusion: a case report of long-term tumor-free survival with crizotinib treatment.伴有NTRK1-KHDRBS1基因融合的未分类间充质肉瘤：克唑替尼治疗长期无瘤生存的病例报告
World J Surg Oncol. 2021 Apr 30;19(1):136. doi: 10.1186/s12957-021-02237-y.
7
High-throughput sequencing detection and ensartinib treatment of lung cancer harboring NTRK1 fusion.携带NTRK1融合的肺癌的高通量测序检测及恩沙替尼治疗
Cancer Commun (Lond). 2021 Feb;41(2):192-196. doi: 10.1002/cac2.12133. Epub 2021 Jan 16.